Mycophenolic acid (MPA) is an immunosuppressive agent used in the management of various autoimmune and inflammatory dermatological conditions. This medication inhibits the proliferation of T and B cells, thereby reducing inflammation and preventing autoantibody formation. MPA is commonly used in the treatment of dermatomyositis, lupus erythematosus, and pemphigus vulgaris. It is also used as a steroid-sparing agent in the management of refractory autoimmune blistering diseases.

MPA is available in both oral and intravenous formulations. Common side effects include gastrointestinal symptoms, bone marrow suppression, and increased risk of infections. The use of MPA requires careful monitoring of blood counts and renal function. In dermatology, MPA is often used as a second-line agent for moderate to severe cases of autoimmune or inflammatory skin diseases that do not respond to conventional therapies.

This learning module covers the pharmacology, mechanisms of action, indications, dosing, adverse effects, drug interactions, and monitoring requirements of mycophenolate acid.

To test your knowledge, we invite you to complete the associated quiz.

Select how you would like to proceed below:

1. Bolognia, J., Cerroni, L., & Schaffer, J. V. (2018). Dermatology. Philadelphia: Elsevier.

2. Wolverton, S. E. (2021). Comprehensive dermatologic drug therapy. Edinburgh: Saunders.